FON-2023-0377.R1_-_Revised_Supplementary_Appendix_-_Clean_-_100723.docx (1.87 MB)

Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review - Supplementary material

dataset

posted on 2023-09-08, 08:24 authored by Robert Hettle, Adela Mihai, Shona H Lang, Sophie Tatman, Stephanie L Swift

Supplementary Appendix

Supplementary Figures 1-4

Supplementary Tables 1-25

Funding

AstraZeneca UK, (Grant / Award Number: ) Merck Sharp and Dohme, (Grant / Award Number:)

History

Usage metrics

Categories

Oncology and carcinogenesis not elsewhere classified

Keywords

abiraterone burden cancer enzalutamide mCRPC metastatic castrate-resistant prostate cancer next-generation hormonal agent prostate real-world evidence

Licence

CC BY-NC-ND 4.0

Exports